Bengal Physician Journal

Register      Login

VOLUME 7 , ISSUE 3 ( September-December, 2020 ) > List of Articles


Optimizing Noncardiac Prescription in a Cardiac Patient

Ashraf Kader Sahib, Meenakshisundaram Chenniappan

Citation Information : Sahib AK, Chenniappan M. Optimizing Noncardiac Prescription in a Cardiac Patient. Bengal Physician Journal 2020; 7 (3):63-69.

DOI: 10.5005/jp-journals-10070-7032

License: CC BY-NC 4.0

Published Online: 01-12-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Comorbidities are present in greater than 75% of cardiac patients. While choosing therapy for such patients it is important to keep in mind the complex interactions of various drugs in the background of comorbidities. Safety should be the prime concern though the efficacy of the drugs should not be compromised too much. This article touches upon the therapy of cardiac patients with anemia, diabetes mellitus, kidney disease, thyroid disorders, sleep disorders, psychiatric illness, or malignancies. Drug class, dosage, drug route, or contraindications have been highlighted for optimal management.

  1. Dunlay SM, Westo SA, Redfield MM, et al. Anemia and heart failure: a community study. Am J Med 2008;121(8):726–732. DOI: 10.1016/j.amjmed.2008.03.039.
  2. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update on the guidelines for the management of heart failure: a report of the American college of cardiology/American Heart Association task force on clinical practice. Circulation 2017;136:e137–e161. DOI: 10.1161/CIR.0000000000000509.
  3. Cigarroa RG, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86(6 Pt 1):649–652. DOI: 10.1016/0002-9343(89)90437-3.
  4. Virend K Somers, David P White, Raouf Amin, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008;52(8):686–717. DOI: 10.1016/j.jacc.2008.05.002.
  5. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diab Care 2019;42(Supplement 1):S103–S123. DOI: 10.2337/dc19-S010.
  6. Behl S, Misra A. Management of obesity in adult Asian Indians. Indian Heart J 2017;69(4):539–544. DOI: 10.1016/j.ihj.2017.04.015.
  7. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 2016;134(10):e123–e155. DOI: 10.1161/CIR.0000000000000404.
  8. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004;364(9438):937–952. DOI: 10.1016/S0140-6736(04)17018-9.
  9. Pawlosky N. Cardiovascular risk: are all NSAIDs alike? Can Pharm J (Ott) 2013;146(2):80–83. DOI: 10.1177/1715163513481569.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.